Professor Patricia Roxburgh
- Professor of Experimental Cancer Medicine (Clinical Research Garscube)
email:
Patricia.Roxburgh@glasgow.ac.uk
Office 310, Wolfson Wohl Cacer Research Centre, Glasgow G61 1BD
https://orcid.org/0000-0001-9869-591XResearch interests
Research groups
- Gynaecological (uterine/ovarian)
Publications
2024
Krebs, M. G. et al. (2024) Eftilagimod alpha (a soluble LAG-3 protein) combined with pembrolizumab in second-line metastatic NSCLC refractory to anti–programmed cell death protein 1/programmed death-ligand 1-based therapy: final results from a phase 2 study. JTO Clinical and Research Reports, 5(11), 100725. (doi: 10.1016/j.jtocrr.2024.100725) (PMID:39403626)
Drew, Y. et al. (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30(1), pp. 50-62. (doi: 10.1158/1078-0432.ccr-23-2249) (PMID:37939124) (PMCID:PMC10767301)
2023
Alizzi, Z. et al. (2023) Description of a retrospective cohort of epithelial ovarian cancer patients with brain metastases: evaluation of the role of PARP inhibitors in this setting. Journal of Clinical Medicine, 12(7), 2497. (doi: 10.3390/jcm12072497) (PMID:37048581) (PMCID:PMC10095324)
2022
Ho, G.-Y. et al. (2022) Epithelial-to-mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule-targeting with eribulin. Cancer Research, 82(23), pp. 4457-4473. (doi: 10.1158/0008-5472.can-21-4012) (PMID:36206301) (PMCID:PMC9716257)
Hollis, R. L. et al. (2022) Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification. Clinical Cancer Research, 28(16), pp. 3546-3556. (doi: 10.1158/1078-0432.CCR-22-0368) (PMID:35696721)
Spiliopoulou, P. et al. (2022) Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma. Molecular Cancer Therapeutics, 21(4), pp. 522-534. (doi: 10.1158/1535-7163.MCT-21-0743) (PMID:35131874) (PMCID:PMC9377747)
Wohlmuth, C. et al. (2022) CA-125 levels are predictive of survival in low-grade serous ovarian cancer—a multicenter analysis. Cancers, 14(8), 1954. (doi: 10.3390/cancers14081954) (PMID:35454861) (PMCID:PMC9024456)
2021
Moreno, V. et al. (2021) Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. Journal for ImmunoTherapy of Cancer, 9(12), e003645. (doi: 10.1136/jitc-2021-003645) (PMID:34893524) (PMCID:PMC8666888)
Spiliopoulou, P. , Hinsley, S. , Mcneish, I. A. , Roxburgh, P. and Glasspool, R. (2021) Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 31, pp. 1037-1044. (doi: 10.1136/ijgc-2021-002467) (PMID:34016703)
Ewing, A. et al. (2021) Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma. Clinical Cancer Research, 27(11), pp. 3201-3214. (doi: 10.1158/1078-0432.CCR-20-4068) (PMID:33741650) (PMCID:PMC7610896)
2020
Litchfield, K. et al. (2020) Representative sequencing: unbiased sampling of solid tumor tissue. Cell Reports, 31(5), 107550. (doi: 10.1016/j.celrep.2020.107550) (PMID:32375028)
2017
Wilson, R. H. et al. (2017) A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer, 116(884), (doi: 10.1038/bjc.2017.36) (PMID:28222073)
2014
Roxburgh, P. , Lumsden, G. R., Paul, J. , Harden, S., Sweeting, L., James, A., Crellin, A., Morrison, R., Evans, T. R. J. and McDonald, A. C. (2014) A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 74(1), pp. 131-139. (doi: 10.1007/s00280-014-2470-4) (PMID:24819683)
Roxburgh, P. , Cowell, G. M. and Glasspool, R. M. (2014) Concerning the feasibility of obtaining biopsies for research in relapsed ovarian cancer. International Journal of Gynecological Cancer, 24(1), pp. 2-3. (doi: 10.1097/IGC.0000000000000060)
Paulus-Hock, V., Cheung, E. C., Roxburgh, P. , Vousden, K. H. and Hock, A. K. (2014) iRFP is a real time marker for transformation based assays in high content screening. PLoS ONE, 9(6), e98399. (doi: 10.1371/journal.pone.0098399) (PMID:24887316) (PMCID:PMC4041769)
Roxburgh, P. and Glasspool, R. (2014) Squamous carcinoma of the ovary. Current Oncology Reports, 16(413), (doi: 10.1007/s11912-014-0413-1)
2013
Dickens, M.P., Roxburgh, P. , Hock, A., Mezna, M., Kellam, B., Vousden, K.H. and Fischer, P.M. (2013) 5-deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2. Bioorganic and Medicinal Chemistry, 21(22), pp. 6868-6877. (doi: 10.1016/j.bmc.2013.09.038)
Lindsay, C. R., Roxburgh, P. and Graham, J. (2013) How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer? Future Oncology, 9(6), pp. 825-829. (doi: 10.2217/fon.13.60)
Tan, D.S.P., Yap, T.A., Hutka, M., Roxburgh, P. , Ang, J., Banerjee, S., Grzybowska, E., Gourley, C., Gore, M.E. and Kaye, S.B. (2013) Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. European Journal of Cancer, 49(6), pp. 1246-1253. (doi: 10.1016/j.ejca.2012.11.016)
Roxburgh, P. , Hock, A.K., Dickens, M.P., Mezna, M., Fischer, P.M. and Vousden, K.H. (2013) Small molecules that bind the Mdm2 RING stabilize and activate p53. Carcinogenesis, 34(3), pp. 791-798. (doi: 10.1093/carcin/bgs092)
2011
Lolkema, M. P. et al. (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clinical Cancer Research, 17(3), pp. 581-588. (doi: 10.1158/1078-0432.CCR-10-2159)
Roxburgh, P. , Reed, N. and Glasspool, R. (2011) Experience of weekly carboplatin and paclitaxel in treatment resistant ovarian cancer. European Journal of Clinical and Medical Oncology, 3(4),
2010
Gourley, C. et al. (2010) Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. Journal of Clinical Oncology, 28(15), pp. 2505-2511. (doi: 10.1200/JCO.2009.25.1082)
2008
Roxburgh, P. and Evans, T. (2008) Systemic therapy of hepatocellular carcinoma: Are we making progress? Advances in Therapy, 25(11), pp. 1089-1104. (doi: 10.1007/s12325-008-0113-z)
Articles
Krebs, M. G. et al. (2024) Eftilagimod alpha (a soluble LAG-3 protein) combined with pembrolizumab in second-line metastatic NSCLC refractory to anti–programmed cell death protein 1/programmed death-ligand 1-based therapy: final results from a phase 2 study. JTO Clinical and Research Reports, 5(11), 100725. (doi: 10.1016/j.jtocrr.2024.100725) (PMID:39403626)
Drew, Y. et al. (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30(1), pp. 50-62. (doi: 10.1158/1078-0432.ccr-23-2249) (PMID:37939124) (PMCID:PMC10767301)
Alizzi, Z. et al. (2023) Description of a retrospective cohort of epithelial ovarian cancer patients with brain metastases: evaluation of the role of PARP inhibitors in this setting. Journal of Clinical Medicine, 12(7), 2497. (doi: 10.3390/jcm12072497) (PMID:37048581) (PMCID:PMC10095324)
Ho, G.-Y. et al. (2022) Epithelial-to-mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule-targeting with eribulin. Cancer Research, 82(23), pp. 4457-4473. (doi: 10.1158/0008-5472.can-21-4012) (PMID:36206301) (PMCID:PMC9716257)
Hollis, R. L. et al. (2022) Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification. Clinical Cancer Research, 28(16), pp. 3546-3556. (doi: 10.1158/1078-0432.CCR-22-0368) (PMID:35696721)
Spiliopoulou, P. et al. (2022) Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma. Molecular Cancer Therapeutics, 21(4), pp. 522-534. (doi: 10.1158/1535-7163.MCT-21-0743) (PMID:35131874) (PMCID:PMC9377747)
Wohlmuth, C. et al. (2022) CA-125 levels are predictive of survival in low-grade serous ovarian cancer—a multicenter analysis. Cancers, 14(8), 1954. (doi: 10.3390/cancers14081954) (PMID:35454861) (PMCID:PMC9024456)
Moreno, V. et al. (2021) Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. Journal for ImmunoTherapy of Cancer, 9(12), e003645. (doi: 10.1136/jitc-2021-003645) (PMID:34893524) (PMCID:PMC8666888)
Spiliopoulou, P. , Hinsley, S. , Mcneish, I. A. , Roxburgh, P. and Glasspool, R. (2021) Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 31, pp. 1037-1044. (doi: 10.1136/ijgc-2021-002467) (PMID:34016703)
Ewing, A. et al. (2021) Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma. Clinical Cancer Research, 27(11), pp. 3201-3214. (doi: 10.1158/1078-0432.CCR-20-4068) (PMID:33741650) (PMCID:PMC7610896)
Litchfield, K. et al. (2020) Representative sequencing: unbiased sampling of solid tumor tissue. Cell Reports, 31(5), 107550. (doi: 10.1016/j.celrep.2020.107550) (PMID:32375028)
Wilson, R. H. et al. (2017) A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer, 116(884), (doi: 10.1038/bjc.2017.36) (PMID:28222073)
Roxburgh, P. , Lumsden, G. R., Paul, J. , Harden, S., Sweeting, L., James, A., Crellin, A., Morrison, R., Evans, T. R. J. and McDonald, A. C. (2014) A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 74(1), pp. 131-139. (doi: 10.1007/s00280-014-2470-4) (PMID:24819683)
Roxburgh, P. , Cowell, G. M. and Glasspool, R. M. (2014) Concerning the feasibility of obtaining biopsies for research in relapsed ovarian cancer. International Journal of Gynecological Cancer, 24(1), pp. 2-3. (doi: 10.1097/IGC.0000000000000060)
Paulus-Hock, V., Cheung, E. C., Roxburgh, P. , Vousden, K. H. and Hock, A. K. (2014) iRFP is a real time marker for transformation based assays in high content screening. PLoS ONE, 9(6), e98399. (doi: 10.1371/journal.pone.0098399) (PMID:24887316) (PMCID:PMC4041769)
Roxburgh, P. and Glasspool, R. (2014) Squamous carcinoma of the ovary. Current Oncology Reports, 16(413), (doi: 10.1007/s11912-014-0413-1)
Dickens, M.P., Roxburgh, P. , Hock, A., Mezna, M., Kellam, B., Vousden, K.H. and Fischer, P.M. (2013) 5-deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2. Bioorganic and Medicinal Chemistry, 21(22), pp. 6868-6877. (doi: 10.1016/j.bmc.2013.09.038)
Lindsay, C. R., Roxburgh, P. and Graham, J. (2013) How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer? Future Oncology, 9(6), pp. 825-829. (doi: 10.2217/fon.13.60)
Tan, D.S.P., Yap, T.A., Hutka, M., Roxburgh, P. , Ang, J., Banerjee, S., Grzybowska, E., Gourley, C., Gore, M.E. and Kaye, S.B. (2013) Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. European Journal of Cancer, 49(6), pp. 1246-1253. (doi: 10.1016/j.ejca.2012.11.016)
Roxburgh, P. , Hock, A.K., Dickens, M.P., Mezna, M., Fischer, P.M. and Vousden, K.H. (2013) Small molecules that bind the Mdm2 RING stabilize and activate p53. Carcinogenesis, 34(3), pp. 791-798. (doi: 10.1093/carcin/bgs092)
Lolkema, M. P. et al. (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clinical Cancer Research, 17(3), pp. 581-588. (doi: 10.1158/1078-0432.CCR-10-2159)
Roxburgh, P. , Reed, N. and Glasspool, R. (2011) Experience of weekly carboplatin and paclitaxel in treatment resistant ovarian cancer. European Journal of Clinical and Medical Oncology, 3(4),
Gourley, C. et al. (2010) Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. Journal of Clinical Oncology, 28(15), pp. 2505-2511. (doi: 10.1200/JCO.2009.25.1082)
Roxburgh, P. and Evans, T. (2008) Systemic therapy of hepatocellular carcinoma: Are we making progress? Advances in Therapy, 25(11), pp. 1089-1104. (doi: 10.1007/s12325-008-0113-z)
Grants
Grants and Awards listed are those received whilst working with the University of Glasgow.
- Genomic landscape of ovarian cancer tumour genesis in high risk BRCA 1/2 mutation carriers
Tenovus Scotland
2025 - 2025
- Integrating Medically Actionable Genomics INto Early-phase (IMAGINE)
Beatson Cancer Charity
2024 - 2026
- ECMC QQR 2023-2028
Cancer Research UK
2023 - 2024
- Dissecting the transcription regulatory network in malaria parasites at early transmission stages
Cancer Research UK
2022 - 2025
- CRUK Centre Renewal 2021
Cancer Research UK
2022 - 2023
- CRUK Centre Renewal 2021
Cancer Research UK
2022 - 2024
- PAIRS: Parp Inhibitor Resistance Study
Wellbeing of Women
2022 - 2026
- NHS Ovarian cancer research project - Patricia Roxburgh
NHS Greater Glasgow and Clyde
2020 - 2021
- the PEACE study
NHS Greater Glasgow and Clyde
2018 - 2021
- Precision Medicine Laboratory sequencing of patient tumour samples
Beatson Cancer Charity
2017 - 2022
- Developing personalised therapy for women with ovarian cancer
Beatson Cancer Charity
2016 - 2019
- The relationship between p53 mutation and inflammation in high-grade serous ovarian cancer
Academy of Medical Sciences
2014 - 2015
- p53 mutation as a biomarker for response to anti-EGFR therapy in metastatic colorectal cancer
Cancer Research UK
2010 - 2012